Drugs / SF6
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT02748798 | Nov 2020 → Oct 2021 | asbestosis, asthma, bronchiectasis, common cold +9 | Thunder Bay Regional Health Research Institute | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SF6 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02748798 ↗ |
| Modality | Diagnostic / imaging agent | “The goal of this research is to optimize the MRI system to obtain ideal lung images using Hyperpolarized (HP) Noble and Inert Fluorinated Gases as contrast agents.” NCT02748798 ↗ |
| Route | Inhaled | “Participants will inhale investigational gases (HP 3He, HP 129Xe, PFP and SF6) according to the procedure for that intervention.” NCT02748798 ↗ |